S-1 + capecitabine cost-effective option in metastatic colorectal cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2020 Category: Drugs & Pharmacology Source Type: news

Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers
             Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Blueprint Medicines Corporation (NASDAQ:BPMC), today announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialisation outside the United States (US), excluding Greater China*. In the US, Genentech, a member of the Roche Group, will obtain co-commercialisation rights to pralsetinib, Blueprint Medicine ’s investigational, once-daily oral precision therapy for the treatment of people with RET-altered ...
Source: Roche Media News - July 14, 2020 Category: Pharmaceuticals Source Type: news

Early Breast Cancer Highlights From ASCO 2020 Early Breast Cancer Highlights From ASCO 2020
Early breast cancer highlights from ASCO 2020 include refinement of adjuvant regimens in HER2+, selection of patients for chemo in ER+, and large-dose capecitabine maintenance in operable TNBC.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 24, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Tucatinib Combination Induces Positive Intracranial Responses in HER2-Positive Breast Cancer Brain Metastases
Tucatinib in combination with trastuzumab and capecitabine yielded significant intracranial responses in patients with previously treated HER2-positive metastatic breast cancer and brain metastases. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2020 Category: Cancer & Oncology Authors: Lisa Astor Source Type: news

Tucatinib Improves PFS, OS in HER2+ BC With Brain Metastases Tucatinib Improves PFS, OS in HER2+ BC With Brain Metastases
In HER2-positive breast cancer patients with brain metastases treated with trastuzumab and capecitabine, tucatinib increased median overall survival from 12 months to 18.1 months in a phase 2 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 31, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Tukysa Approved for Unresectable, Metastatic HER2-Positive Breast Cancer
MONDAY, April 20, 2020 -- The U.S. Food and Drug Administration announced Friday the approval of Tukysa (tucatinib) in combination with trastuzumab and capecitabine for treatment of advanced unresectable or metastatic human epidermal growth factor... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 20, 2020 Category: General Medicine Source Type: news

FDA Approves Tukysa (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer
BOTHELL, Wash.--(BUSINESS WIRE) April 17, 2020 -- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the U.S. Food and Drug Administration (FDA) granted approval to Tukysa™ (tucatinib) tablets in combination with trastuzumab and capecitabine... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 18, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves sNDA for Neratinib in Combination with Capecitabine for HER2+ Breast Cancer
The FDA approved a supplemental new drug application for neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received at least 2 prior anti-HER2-based regimens in the metastatic setting. (Source: CancerNetwork)
Source: CancerNetwork - February 26, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Study finds less-aggressive chemotherapy after initial treatment for metastatic colorectal cancer to be more beneficial
PHOENIX -- A Mayo Clinic study involving 5,540 patients with metastatic colorectal cancer finds that maintenance chemotherapy after initial treatment is more beneficial for patients whose disease is under control, compared with more aggressive treatment. A maintenance strategy with a fluoropyrimidine chemotherapy, such as 5-FU or capecitabine, is preferred, though observation with no chemotherapy is [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - December 19, 2019 Category: Research Source Type: news

New Standard Likely for Some Metastatic HER2 Breast Cancer New Standard Likely for Some Metastatic HER2 Breast Cancer
The investigational oral therapy tucatinib, when added to standard trastuzumab and capecitabine, resulted in a"clinically meaningful" lower risk of disease progression or death compared with placeboMedscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 11, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

SABCS: Addition of Tucatinib Ups Survival in HER2 & #43; Metastatic Breast Cancer
WEDNESDAY, Dec. 11, 2019 -- Adding tucatinib to trastuzumab and capecitabine is associated with improved progression-free and overall survival among heavily pretreated patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 11, 2019 Category: Pharmaceuticals Source Type: news

Dana-Farber Study: New Drugs Show Rare Promise Against Advanced Breast Cancer
SAN ANTONIO (AP) — Doctors on Wednesday reported unusually good results from tests of two experimental drugs in women with an aggressive form of breast cancer that had spread widely and resisted many previous treatments. One drug showed particular ability to reach tumors in the brain, which are notoriously tough to treat. The other pairs a sort of homing device for cancer cells with a payload of chemotherapy that’s released when it reaches its target. “It’s a guided missile. It’s able to bring the chemotherapy directly to the cancer cell,” said the study leader, Dr. Ian Krop of the Dana-...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - December 11, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Syndicated CBSN Boston Breast Cancer Dana Farber Cancer Institute Source Type: news

Adding tucatinib to drug combination extends survival for advanced HER2+ breast cancer patients
(University of Texas M. D. Anderson Cancer Center) Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing the addition of tucatinib to capecitabine (Xeloda) and trastuzumab (Herceptin) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced HER2-positive breast cancer, with and without brain metastasis according to results of the HER2CLIMB clinical trial. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2019 Category: Cancer & Oncology Source Type: news

Standard Adjuvant Chemotherapy Compared to Capecitabine in Early Breast Cancer
Researchers followed up 10 years after the CALGB 49907 trial to see which treatment led to longer  recurrence-free survival. (Source: CancerNetwork)
Source: CancerNetwork - August 27, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

capecitabine (Xeloda)
Title: capecitabine (Xeloda)Category: MedicationsCreated: 12/14/2000 12:00:00 AMLast Editorial Review: 8/6/2019 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 6, 2019 Category: Cancer & Oncology Source Type: news

ASCO: Low - Dose Chemo Benefits Advanced Gastroesophageal Cancer
Elderly, frail receiving 60 percent of oxaliplatin/capecitabine dose have noninferior PFS, less toxicity (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 3, 2019 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pharmacy, Geriatrics, Conference News, Source Type: news

Digital Pill May Improve Adherence to Oral Cancer Drugs Digital Pill May Improve Adherence to Oral Cancer Drugs
Oral drugs combined with a sensor can alert clinicians and caregivers when medication has been taken; a pilot trial with a digital capecitabine is underway in colorectal cancer patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 6, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Proteus debuts digital cancer drug
Proteus Digital Health said today that the first cancer patients were treated using its digital oncology therapy, which combines oral chemotherapy with an ingestible sensor. Patients with stage 3 and 4 colorectal cancer at the University of Minnesota Health and Fairview Health Services were treated with digital capecitabine. The Redwood City, Calif.-based company plans to use its sensor-drug combination to record and share data such as the time and dose of chemotherapy that a patient ingests. Get the full story at our sister site, Drug Delivery Business News. The post Proteus debuts digital cancer drug appeared first ...
Source: Mass Device - January 17, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Featured mHealth (Mobile Health) Oncology Pharmaceuticals Proteus Digital Health Source Type: news

TNBC Study of Capecitabine Mostly Disappoints, With One Exception TNBC Study of Capecitabine Mostly Disappoints, With One Exception
A study of adjuvant capecitabine in triple-negative breast cancer was largely negative, but disease-free and overall survival were improved in a subset of patients with the nonbasal-like phenotype.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - December 6, 2018 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Xeloda Disappoints in Early Triple-Negative Breast Cancer
(MedPage Today) -- No improvement after standard chemo, though subset may derive some benefit (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 6, 2018 Category: Hematology Source Type: news

Adjuvant capecitabine did not improve outcomes for patients with early triple-negative breast cancer
(American Association for Cancer Research) Treating patients who had early-stage triple-negative breast cancer with the chemotherapy agent capecitabine after they completed surgery and standard chemotherapy did not significantly improve disease-free or overall survival compared with observation, according to data from the randomized, phase III GEICAM/CIBOMA clinical trial presented at the 2018 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 5, 2018 Category: Cancer & Oncology Source Type: news

Capecitabine + bevacizumab in CRC: small benefit, high cost in US
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 1, 2018 Category: Drugs & Pharmacology Source Type: news

Combo Tx Boosts PFS in Advanced pNETs
(MedPage Today) -- Unprecedented 22-month median with temozolomide-capecitabine (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - October 7, 2018 Category: Endocrinology Source Type: news

Real-world adverse effects of capecitabine toxicity in an elderly population - van Beek MWH, Roukens M, Jacobs WCH, Timmer-Bonte JNH, Kramers C.
BACKGROUND: Few studies have assessed the safety and effectiveness of the numerous available chemotherapeutic therapies for geriatric oncology patients. Most safety studies are conducted in large trials, and there is some uncertainty surrounding whether th... (Source: SafetyLit)
Source: SafetyLit - July 2, 2018 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Tucatinib Shows Promise in Phase I Study of HER2-Positive Breast Cancer
The HER2 TKI tucatinib plus capecitabine or trastuzumab were reasonably well tolerated and showed antitumor activity in a phase I trial of HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 12, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

'I'm so lucky my cancer was spotted after budget cuts hit screening' says LORD LANSLEY
LAST Monday, I sat in a chair in a medical day unit while chemotherapy medication went into my vein. A drug called oxaliplatin which, with daily tablets of capecitabine to follow, are my ongoing treatment for bowel cancer. (Source: Daily Express - Health)
Source: Daily Express - Health - April 4, 2018 Category: Consumer Health News Source Type: news

3, 6 Month Adjuvant CAPOX Equally Effective for Colon Cancer
THURSDAY, March 29, 2018 -- For patients with stage III colon cancer, three months of capecitabine and oxaliplatin (CAPOX) therapy is not noninferior to six months of therapy overall, according to a study published in the March 20 issue the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 30, 2018 Category: Pharmaceuticals Source Type: news

36% Price Drop With a Generic Oral Chemo: Good Enough? 36% Price Drop With a Generic Oral Chemo: Good Enough?
Capecitabine was one of the first oral chemotherapies to come off patent, and the generic version has been quickly accepted.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 12, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Generics do not contain branded capecitabine costs in USA
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - September 1, 2017 Category: Drugs & Pharmacology Source Type: news

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
This research article has led to a Practice Changing Update on DynaMed Plus. It concludes that capecitabine adjuvant therapy may improve survival in women with HER2-negative residual invasive breast cancer after neoadjuvant chemotherapy (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 19, 2017 Category: Consumer Health News Source Type: news

Adjuvant Capecitabine for Breast Cancer Can Replace CMF After Epirubicin
Replacing a cyclophosphamide-based regimen with oral capecitabine does not sacrifice efficacy in adjuvant therapy for early breast cancer, and improves quality of life, according to a new study. (Source: CancerNetwork)
Source: CancerNetwork - June 28, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer News Source Type: news

Your NEJM Group Today: Diabetic Foot Ulcer Recurrence / Capecitabine & Postsurgical Residual Breast Cancer / Colorado Cardiology Opportunity (FREE)
By the Editors Here's what we chose for you from NEJM Group today:NEJM Clinical Practice Center: Review: Foot ulceration is the most common lower-extremity complication … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 19, 2017 Category: Primary Care Source Type: news

Adjuvant Capecitabine Improves Survival in Residual Invasive Breast Cancer
Patients with HER2-negative breast cancer with residual invasive disease following neoadjuvant chemotherapy benefit from adjuvant treatment with capecitabine. (Source: CancerNetwork)
Source: CancerNetwork - June 14, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer News Source Type: news

New chemotherapy approach offers breast cancer patients a better quality of life
(Cancer Research UK) The chemotherapy drug capecitabine gives patients a better quality of life and is as effective at preventing breast cancer from returning as the alternative regimen called CMF, when given following epirubicin. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 6, 2017 Category: Cancer & Oncology Source Type: news

Neratinib Shrunk Brain Mets in Half of HER2+ Breast Cancer Patients
This video examines results of a phase II trial that studied the combination of neratinib plus capecitabine for the treatment of recurrent brain metastases in HER2-positive breast cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2017 Category: Cancer & Oncology Authors: Rachel A. Freedman, MD, MPH Tags: Conferences/ASCO Breast Cancer HER2-Positive Breast Cancer Videos Breast Cancer Source Type: news

Neratinib Shrank Brain Mets in Half of HER2+ Breast Cancer Patients
This video examines results of a phase II trial that studied the combination of neratinib plus capecitabine for the treatment of recurrent brain metastases in HER2-positive breast cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2017 Category: Cancer & Oncology Authors: Rachel A. Freedman, MD, MPH Tags: Conferences/ASCO Breast Cancer HER2-Positive Breast Cancer News Videos Breast Cancer Source Type: news

Certain Breast CA Patients Benefit From Adjuvant Capecitabine
Capecitabine cut risk of relapse, death by 30 percent over five years, researchers say (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 1, 2017 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Radiology, Surgery, Journal, Source Type: news

Drug Xeloda Prolongs Survival for Some Breast Cancer Patients
Title: Drug Xeloda Prolongs Survival for Some Breast Cancer PatientsCategory: Health NewsCreated: 5/31/2017 12:00:00 AMLast Editorial Review: 6/1/2017 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - June 1, 2017 Category: Cancer & Oncology Source Type: news

Drug Xeloda Prolongs Survival for Some Breast Cancer Patients
It cut risk of relapse, death by 30 percent over 5 years, trial found (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - June 1, 2017 Category: Cancer & Oncology Source Type: news

Drug Xeloda Prolongs Survival for Some Breast Cancer Patients
It cut risk of relapse, death by 30 percent over 5 years, trial found (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 1, 2017 Category: Cancer & Oncology Tags: Oncology, News, Source Type: news

Drug Xeloda Prolongs Survival for Some Breast Cancer Patients
It cut risk of relapse, death by 30 percent over 5 years, trial found Source: HealthDay Related MedlinePlus Pages: Breast Cancer (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 31, 2017 Category: Consumer Health News Source Type: news

Drug Xeloda Prolongs Survival for Some Breast Cancer Patients
WEDNESDAY, May 31, 2017 -- A drug called Xeloda can extend the lives of some women whose breast cancer is not wiped out by standard treatment, a new clinical trial finds. Oncologists said the results are " practice-changing. " " This drug is already... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 31, 2017 Category: General Medicine Source Type: news

ASCO: Capecitabine May Extend Survival in Biliary Tract Cancer
Survival benefit seen in those given capecitabine versus surgery alone (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 20, 2017 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pharmacy, Conference News, Source Type: news

Chemo Drug May Buy Time for Those With Bile Duct Cancer
For patients with the rare disease, survival benefit was seen in those given Xeloda, researchers say (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 19, 2017 Category: Cancer & Oncology Tags: Family Medicine, Gastroenterology, Nursing, Oncology, News, Source Type: news

Chemo Drug May Buy Time for Those with Bile Duct Cancer
For patients with the rare disease, survival benefit was seen in those given Xeloda, researchers say Source: HealthDay Related MedlinePlus Pages: Bile Duct Cancer, Cancer Chemotherapy (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 18, 2017 Category: Consumer Health News Source Type: news

Adjuvant Oral Chemo in Biliary Tract Cancer Extended Survival
The addition of adjuvant oral chemotherapy with capecitabine extended the overall survival of patients with biliary cancers by a median of 15 months, according to the results of the BILCAP study. (Source: CancerNetwork)
Source: CancerNetwork - May 18, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO Gastrointestinal Cancer Liver, Gallbladder, and Biliary Tract Cancers News Source Type: news

Chemo Drug, Xeloda, May Buy Time for Those With Bile Duct Cancer
THURSDAY, May 18, 2017 -- The chemotherapy drug Xeloda may prolong survival in those struck by a type of digestive system cancer, a new study finds. People with bile duct cancer who received the medication lived for an average of about 17 months... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 18, 2017 Category: General Medicine Source Type: news

Chemo Drug May Buy Time for Those With Bile Duct Cancer
THURSDAY, May 18, 2017 -- The chemotherapy drug Xeloda may prolong survival in those struck by a type of digestive system cancer, a new study finds. People with bile duct cancer who received the medication lived for an average of about 17 months... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 18, 2017 Category: General Medicine Source Type: news

Chemo Drug May Buy Time for Those With Bile Duct Cancer
For patients with the rare disease, survival benefit was seen in those given Xeloda, researchers say (Source: Cancercompass News: Colorectal Cancer)
Source: Cancercompass News: Colorectal Cancer - May 18, 2017 Category: Cancer & Oncology Source Type: news

Capecitabine improves post-surgery survival period in bile duct cancer patients
A Cancer Research UK-funded trial (BILCAP) showed that the chemotherapy drug capecitabine increased the survival period of bile duct cancer patients by up to one and a half years after undergoing surgery for the disease. (Source: Drug Development Technology)
Source: Drug Development Technology - May 18, 2017 Category: Pharmaceuticals Source Type: news